Terumo Corporation (TRUMY)

Terumo Corporation (TRUMY) Healthcare & Pipeline Overview

Terumo Corporation, a Japanese medical device manufacturer, develops, produces, and distributes a diverse portfolio of medical products and equipment across three segments, including cardiac and vascular, medical care solutions, and blood and cell technologies, serving a global healthcare market with a focus on innovation and quality.

What Is the Investment Thesis for TRUMY?

Terumo Corporation presents a compelling investment case based on its diversified product portfolio, global presence, and consistent profitability. With a market capitalization of $20.79B and a P/E ratio of 24.1, Terumo demonstrates financial stability. The company's 11.7% profit margin and 53.3% gross margin indicate efficient operations. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. Potential risks include regulatory changes in the medical device industry and increased competition from established players and new entrants. The company's beta of 0.25 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

TRUMY Key Highlights

• Market capitalization of $20.79B, reflecting its significant presence in the medical device industry.
• P/E ratio of 24.1, indicating investor confidence in its earnings potential.
• Profit margin of 11.7%, showcasing efficient operations and profitability.
• Gross margin of 53.3%, highlighting the company's ability to maintain strong pricing power.
• Dividend yield of 1.35%, providing a steady income stream for investors.

Who Are TRUMY's Competitors?

TRUMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TRUMY's Key Strengths?

• Diversified product portfolio
• Global presence and distribution network
• Strong brand reputation
• Consistent profitability

What Are TRUMY's Weaknesses?

• Exposure to currency fluctuations
• Dependence on regulatory approvals
• Limited presence in certain emerging markets
• Potential for product recalls

What Could Drive TRUMY Stock Higher?

• Continued innovation in cardiac and vascular devices, leading to new product launches and market share gains.
• Expansion in emerging markets, driving revenue growth and increasing global presence.
• Potential strategic acquisitions to expand product portfolio and geographic reach.
• Growth in contract manufacturing services for pharmaceutical companies, providing a stable revenue stream.

What Are the Key Risks for TRUMY?

• Increased competition from established players and new entrants in the medical device industry.
• Regulatory changes in the medical device industry, impacting product approvals and market access.
• Exposure to currency fluctuations, affecting financial results and profitability.
• Product liability claims and recalls, potentially damaging brand reputation and financial performance.

What Are the Growth Opportunities for TRUMY?

• Expansion in Emerging Markets: Terumo has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Terumo's products, particularly in the cardiac and vascular and medical care solutions segments. The rising prevalence of chronic diseases and increasing access to healthcare in these regions are expected to drive demand for Terumo's medical devices and equipment. Timeline: Ongoing.
• Innovation in Cardiac and Vascular Devices: Terumo can continue to invest in research and development to develop innovative cardiac and vascular devices, such as drug-eluting stents and advanced imaging catheters. These products can address unmet clinical needs and improve patient outcomes, driving revenue growth and market share gains. The global market for cardiac and vascular devices is expected to grow at a steady pace, driven by the increasing prevalence of cardiovascular diseases. Timeline: Ongoing.
• Growth in Blood and Cell Technologies: Terumo can capitalize on the growing demand for blood and cell technologies, such as blood bags, component collection systems, and cell expansion systems. These products are essential for blood banks, hospitals, and research institutions. The increasing demand for blood transfusions and cell therapies is expected to drive growth in this segment. Timeline: Ongoing.
• Strategic Acquisitions: Terumo can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing competitiveness. The medical device industry is characterized by consolidation, and Terumo can leverage acquisitions to strengthen its position in the market. Timeline: Ongoing.
• Contract Manufacturing for Pharmaceutical Companies: Terumo can expand its contract manufacturing services for pharmaceutical companies, providing prefilled syringes, devices for drug kits, and other products. This business offers a stable revenue stream and leverages Terumo's manufacturing expertise and infrastructure. The increasing demand for prefilled syringes and drug delivery devices is expected to drive growth in this segment. Timeline: Ongoing.

What Opportunities Does TRUMY Have?

• Expansion in emerging markets
• Development of innovative products
• Strategic acquisitions
• Growth in contract manufacturing

What Threats Does TRUMY Face?

• Increased competition
• Regulatory changes
• Economic downturns
• Product liability claims

What Are TRUMY's Competitive Advantages?

• Strong brand reputation for quality and reliability.
• Diversified product portfolio across multiple medical specialties.
• Global presence with established distribution networks.
• Continuous innovation and investment in research and development.

What Does TRUMY Do?

Terumo Corporation, founded in 1921 as Sekisen Ken-onki Corporation, initially focused on manufacturing clinical thermometers. Over the decades, Terumo expanded its product line and global presence, becoming a leading manufacturer of medical devices and equipment. In October 1974, the company officially changed its name to Terumo Corporation. Today, Terumo operates through three primary segments: Cardiac and Vascular Company, which offers products such as angiographic guidewires, catheters, and stents; Medical Care Solutions Company, providing syringes, infusion pumps, and I.V. solutions; and Blood and Cell Technologies Company, which focuses on blood bags, collection systems, and cell expansion systems. Terumo's products are used in a wide range of medical settings, from hospitals and clinics to home healthcare. With its headquarters in Tokyo, Japan, Terumo has a global reach, serving customers in numerous countries and regions. The company is committed to innovation and quality, continuously developing new and improved medical technologies to meet the evolving needs of healthcare professionals and patients worldwide.

What Products and Services Does TRUMY Offer?

• Manufactures and sells angiographic guidewires and catheters.
• Produces vascular closure devices and PTCA balloon catheters.
• Develops and distributes coronary and peripheral stents.
• Offers intravascular ultrasound systems and imaging catheters.
• Provides oxygenators and cardio-pulmonary bypass systems.
• Manufactures syringes, infusion pumps, and I.V. solutions.
• Offers blood glucose monitoring systems and blood pressure monitors.
• Develops blood bags and component collection systems.

How Does TRUMY Make Money?

• Develops and manufactures a wide range of medical devices and equipment.
• Sells products through direct sales, distributors, and partnerships.
• Generates revenue from three main segments: Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies.
• Invests in research and development to innovate new products and improve existing ones.

What Industry Does TRUMY Operate In?

Terumo Corporation operates in the global medical device industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Terumo competes with other major players in the medical device market, including CLPBF, CLPBY, KONEF, OCPNF, and OTSKF. The company's diversified product portfolio and global presence provide a competitive edge in this dynamic and competitive landscape.

Who Are TRUMY's Key Customers?

• Hospitals and clinics
• Blood banks and transfusion centers
• Research institutions
• Pharmaceutical companies
• Home healthcare providers

How Terumo Corporation Is Valued

Terumo Corporation carries a market capitalization of $20.79B, placing it in the large-cap category. Relative to its peer group, TRUMY's quantitative score of 51/100 is roughly in line with the peer average of 54/100.

Company Profile

Terumo Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Hikaru Samejima. TRUMY has traded publicly since 2010.

ROE 9%Key Financial Metrics

Return on equity for Terumo Corporation stands at 9.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.9%, showing how much profit it generates from its asset base. TRUMY trades at a trailing price-to-earnings ratio of 24.14, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Terumo Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.29 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Terumo Corporation revenue of about $1.14T for fiscal 2026, with EPS near $92.23. The estimate reflects 7 contributing analysts.

TRUMY Financials

TRUMY Latest News

TRUMY Analyst Consensus

TRUMY MoonshotScore

Terumo Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources